Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial
Status:
Completed
Trial end date:
2020-01-09
Target enrollment:
Participant gender:
Summary
Soluble epoxide hydrolase (sEH) is the metabolizing enzyme of epoxyeicosatrienoic acids
(EETs), which may play a role in reducing neuroinflammation and regulating cerebral blood
flow after subarachnoid hemorrhage (SAH). Hypotheses: Pharmacologic inhibition of the sEH
enzyme is safe and will result in increased EETs availability in the blood and cerebrospinal
fluid. This study is a double-blind, placebo-controlled, phase 1b randomized trial to
evaluate the safety and efficacy of GSK2256294, a novel soluble epoxide hydrolase inhibitor
in patients with aneurysmal SAH.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Oregon Health and Science University
Collaborators:
Foundation for Anesthesia Education and Research GlaxoSmithKline